source
- BioMarin halts development of BMN 401 after phase 3 missBioMarin Pharmaceutical announced it is ending all work on its experimental enzyme replacement therapy BMN 401 following a late‑stage trial that did not meet one of two primary goals in patients wi…
- Biopharma job postings rise 15% in Q2 as layoffs fall and M&A activity picks upThe Q2 2026 BioSpace report shows a strengthening biopharma job market, with more openings and fewer layoffs compared with the prior year. Job postings on BioSpace were up 15% year-over-year and 1…